NervGen Pharma Corp. (NGEN)
NASDAQ: NGEN · Real-Time Price · USD
0.00
0.00 (0.00%)
Apr 29, 2026, 9:43 AM EDT - Market open

NervGen Pharma Cash Flow Statement

Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2017
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2017
Net Income
-44.12-24.25-22.38-20.72-12.73
Upgrade
Depreciation & Amortization
0.060.080.150.120.04
Upgrade
Loss (Gain) From Sale of Assets
-0.01---
Upgrade
Stock-Based Compensation
5.396.046.042.774.02
Upgrade
Other Operating Activities
18.510.445.14-2.07-0.03
Upgrade
Change in Accounts Receivable
0.33-0.17-0.220.04-0
Upgrade
Change in Accounts Payable
-0.271.23-0.072.320.32
Upgrade
Change in Other Net Operating Assets
0.59-0.220.06-0.240.11
Upgrade
Operating Cash Flow
-19.5-16.84-11.3-17.78-8.27
Upgrade
Capital Expenditures
---0.01-0.02-0
Upgrade
Sale of Property, Plant & Equipment
--0--
Upgrade
Sale (Purchase) of Intangibles
---0.14--0.04
Upgrade
Other Investing Activities
0.10.06---
Upgrade
Investing Cash Flow
0.10.06-0.14-0.02-0.05
Upgrade
Long-Term Debt Repaid
-0.1-0.1-0.1-0.08-
Upgrade
Net Debt Issued (Repaid)
-0.1-0.1-0.1-0.08-
Upgrade
Issuance of Common Stock
24.7624.430.8722.8521.28
Upgrade
Other Financing Activities
-0.89-1.63--0.13-1.67
Upgrade
Financing Cash Flow
23.7622.70.7722.6419.61
Upgrade
Foreign Exchange Rate Adjustments
0.44-0.31-0.120.690.03
Upgrade
Net Cash Flow
4.85.61-10.795.5211.33
Upgrade
Free Cash Flow
-19.5-16.84-11.3-17.81-8.27
Upgrade
Free Cash Flow Per Share
-0.27-0.25-0.19-0.34-0.21
Upgrade
Levered Free Cash Flow
-6.29-8.74-0.3-3-3.56
Upgrade
Unlevered Free Cash Flow
-6.29-8.74-0.3-2.67-3.56
Upgrade
Change in Working Capital
0.660.84-0.242.110.43
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.